The resolution was issued to combat the Respiratory Syncytial Virus and the serums were acquired by direct contracting. Currently only the American pharmaceutical company produces it globally.
Friday, December 29, 2023
For prevention against Respiratory Syncytial Virus (RSV)the national government awarded the pharmaceutical company Pfizer the direct purchase of 530 thousand doses of vaccines to combat it. The acquisition was excluded from the Witness Price Control of the General Audit Office of the Nation.
The vaccine was purchased by direct hire after the exceptional authorization of the Ministry of Health through the Resolution 4216/2023because currently only Pfizer produces this vaccine at the global level.
The Administrative Decision, which bears the signature of Nicolás Posse (Chief of Staff) and Mario Russo (Secretary of Health), details that a total cost of 28.8 million dollars.
They extend a measure so that Cristina Kirchner does not receive the retroactive payment she claims for her double pension
The contract detailed in the Official Gazette also includes a additional donation by the American pharmaceutical company of more than 71 thousand doses of the vaccine against RSV, a virus that causes respiratory tract infections and is known to be the main cause of hospitalizations for that disease in younger children of one year.
“Will have a favorable impact in the health system,” said Russo, who highlighted the importance of having this vaccine that will provide “a very important protection to risk groups”, since the virus affects to babies, small children and adults, especially those whose immune systems are weakened.
The Anmat (National Food, Drug and Medical Technology Administration) has already approved the vaccine produced by Pfizer and it is expected that the vaccination plan With the incorporation of this serum, it will begin in the second half of 2024, before the next peak of cases expected for those months where cold predominates.
On September 8, 2023, the now former Minister of Health, Carla Vizzottiinformed his provincial colleagues that the entity in charge of controlling medicines, food and medical devices had given the green light to a vaccine aimed at pregnant women against respiratory syncytial virus.
This approval came two weeks after international regulatory bodiessuch as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), will accept the vaccine.
What is Respiratory Syncytial Virus?
Respiratory syncytial virus, also known as respiratory syncytial virus, is a common viral disease. Generally causes mild symptoms similar to a cold but can cause serious lung infectionsespecially in babies, older adults, and people with serious medical problems.
This virus can affect people of all ages, but it is very common in young children and infections usually occur in the season from fall to spring.
According to the medium Medlinepluswho are at greater risk of having a serious infection with the virus are “infants, older adults (especially over 65 years of age), people with chronic heart or lung medical conditions, and people with weakened immune systems.”
RSV transmission occurs through direct contact with infected respiratory fluids and can be very contagious. Prevention focuses on hygienic measures such as frequent hand washing and avoid close contact with sick people.
FP/LT
2023-12-29 12:35:45
#Government #bought #thousand #doses #vaccines #Pfizer #Perfil.com
